Program
vamikibart
Also written as “Vamikibart”, “RO7200220” and “EBI-031”.
Its studies are mostly in Macular Edema, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 50 open or running | phase 3since Dec 6, 2022 | Dec 8, 2021 | none ahead |
| Eleven Biotherapeutics | 10 open or running | phase 1since Jul 19, 2016 | Jul 19, 2016 | none ahead |
- Named in Hoffmann-La Roche’s own pipeline as
RG6179 vamikibart
, phase 4, as of Oct 22, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 19, 2016First study: phase 1 study in Diabetic Macular EdemaNew to Eleven BiotherapeuticsEleven Biotherapeutics · NCT02842541
- Dec 8, 2021Hoffmann-La Roche's first studies: 2 phase 2 studies in Diabetic Macular EdemaNew to Hoffmann-La RocheHoffmann-La Roche · NCT05151744, NCT05151731
- Dec 6, 20222 phase 3 studies in Uveitic Macular EdemaHoffmann-La Roche · NCT05642325, NCT05642312
- Jan 8, 2025Phase 1 study in Diabetic Macular EdemaHoffmann-La Roche · NCT06771271 · 85 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06771271Diabetic Macular Edema · United States | 1 | Completed | Hoffmann-La Roche | Nov 13, 2023 | 85 |
| NCT05642325Uveitic Macular Edema · United States, Argentina, Australia and more | 3 | Completed | Hoffmann-La Roche | May 7, 2025 | 256 |
| NCT05642312Uveitic Macular Edema · United States, Austria, Brazil and more | 3 | Completed | Hoffmann-La Roche | Dec 9, 2024 | 245 |
| NCT05151744Diabetic Macular Edema · United States, Argentina, Canada and more | 2 | Completed | Hoffmann-La Roche | Apr 17, 2024 | 187 |
| NCT05151731Diabetic Macular Edema · United States, Argentina, Canada and more | 2 | Completed | Hoffmann-La Roche | Nov 6, 2024 | 394 |
| NCT02842541Diabetic Macular Edema | 1 | Withdrawn | Eleven Biotherapeutics | Oct 2017 | 0 |
How it is read
Names in the registry
- “Vamikibart”, 4 entries
- “RO7200220”, 1 entry
- “EBI-031”, 1 entry
Conditions, from the studies’ own filings
- Macular Edema, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.